促甲状腺激素抑制治疗及其与分化型甲状腺癌骨代谢相关性研究进展附视频

被引：11

作者：

赵兰岚 ^{[1
]}

姚军 ^{[2
]}

高莹 ^{[2
]}

郭晓蕙 ^{[2
]}

机构：

[1] 民航总医院内分泌科

[2] 北京大学第一医院内分泌科

来源：

中国实用内科杂志 | 2017年 / 02期

关键词：

分化型甲状腺癌; 骨代谢; 促甲状腺激素抑制治疗;

D O I：

10.19538/j.nk2017020120

中图分类号：

R736.1 [甲状腺肿瘤];

学科分类号：

100214 ;

摘要：

<正>甲状腺癌是最常见的恶性肿瘤之一,近年来其发病率有明显上升的趋势,2012年我国甲状腺癌发病率为6.56/10万[1],严重威胁着人类的健康。分化型甲状腺癌（differentiated thyroid cancer,DTC）是甲状腺癌中最常见的病理组织学类型,主要包括甲状腺乳头状癌及甲状腺滤泡状癌,占甲状腺恶性肿瘤的90%以上。目前对于DTC的治疗方式主要包括手术、131I治疗和促甲状腺激素(thyroid stimulating

引用

页码：162 / 165

页数：4

共 12 条

[1] 骨保护素对高龄骨质疏松症患者骨代谢的影响 [J].

乔松 ;

许琦 ;

叶子青 ;

俞志红 ;

谢海宝 ;

金肖青 .

解放军医学杂志, 2015, (06) :472-474

[2] 分化型甲状腺癌相关基因的研究进展 [J].

郝智 ;

崔建英 .

现代肿瘤医学, 2015, 23 (04) :569-571

[3] 131I联合左旋甲状腺素对分化型甲状腺癌术后患者骨代谢的影响 [J].

陈立波 ;

朱瑞森 ;

余永利 ;

罗全勇 ;

陆汉魁 ;

袁志斌 ;

张浩 ;

章振林 .

中华内分泌代谢杂志, 2006, (01) :81-83

[4]

The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma[J] . Mee Kyoung Kim,Kyung-Jin Yun,Min-Hee Kim,Dong-Jun Lim,Hyuk-Sang Kwon,Ki-Ho Song,Moo-Il Kang,Ki Hyun Baek. Bone . 2015

[5] Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression [J].

Tournis, Symeon ;

Antoniou, Julia D. ;

Liakou, Chrysoula G. ;

Christodoulou, John ;

Papakitsou, Evangellia ;

Galanos, Antonios ;

Makris, Konstantinos ;

Marketos, Helen ;

Nikopoulou, Stamatina ;

Tzavara, Ioanna ;

Triantafyllopoulos, Ioannis K. ;

Dontas, Ismene ;

Papaioannou, Nikolaos ;

Lyritis, Georgios P. ;

Alevizaki, Maria .

CLINICAL ENDOCRINOLOGY, 2015, 82 (02) :197-204

[6] Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma [J].

Reverter, Jordi L. ;

Colome, Eulalia ;

Holgado, Susana ;

Aguilera, Eva ;

Soldevila, Berta ;

Mateo, Lourdes ;

Sanmarti, Anna .

ENDOCRINE, 2010, 37 (03) :467-472

[7] Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy [J].

Flynn, Robert W. ;

Bonellie, Sandra R. ;

Jung, Roland T. ;

MacDonald, Thomas M. ;

Morris, Andrew D. ;

Leese, Graham P. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01) :186-193

[8]

Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets?[J] . G Brabant. The Journal of Clinical Endocrinology & Metabolism . 2008 (4)

[9] Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy [J].

Mazokopakis, Elias E. ;

Starakis, Ioannis K. ;

Papadomanolaki, Maria G. ;

Batistakis, Antony G. ;

Papadakis, John A. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) :1369-1373

[10]

Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL–RANK interaction[J] . MasanoriKanatani,ToshitsuguSugimoto,HideakiSowa,TatsuyaKobayashi,MichikoKanzawa,KazuoChihara. J. Cell. Physiol. . 2004 (1)

← 1 2 →